
    
      The study consisted of a single dose course of IGIV-C treatment followed by 28-days of
      post-infusion assessments. The total duration of study participation for each subject was up
      to 28 Â± 2 days. Approximately 50 subjects, ages 18 or greater, were planned to be enrolled in
      the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose
      of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe, and South Africa.
    
  